Eris Lifesciences

    ERIS
    Pharma
    ₹1,337.10
    Price as of 18 Nov 2026, 9:58 pm IST

    Market cap ₹18,551 Cr

    P/E
    26.00
    Day range
    ₹1,315.20 – ₹1,381.10
    52-week range
    ₹1,069.00 – ₹1,740.00
    Volume
    2.05 L
    Open
    ₹1,361.00
    Prev close
    ₹1,361.30

    Latest results · Q2 FY27(consolidated)Revenue ₹892 Cr+12.6%Profit ₹187 Cr+39.2%Margin 21.0%YoY vs the same quarter last year

    1 red flag to read up on

    • medium

      Promoter pledge went up

      21.25% of promoter shares pledged, up from 16.85% · 30 Sept 2026

    From NSE and BSE filings. A flag is a reason to read the filing, not a rating.

    Research profile

    Composite 56 / 100

    Factor percentiles

    Value53
    Quality58
    Momentum45
    Low volatility69

    Derived metrics

    Earn. yield
    3.8%
    Graham no.
    ₹608.42
    vs Graham
    -54.5%
    ROE ÷ P/B
    4.4%
    12-1 mom.
    -28.1%
    Return / vol
    -0.54
    Magic Formula
    #310
    Piotroski
    4/6
    FCF yield
    1.3%
    PEG
    0.66

    Percentiles rank this stock against the other tracked stocks and change as they do. Scans describe where figures sit today. Hover a label for its definition. Not investment advice.

    Peer comparison

    All 68 in Pharma
    Largest Pharma companies tracked, with sector medians
    CompanyM-capP/EP/BROEROCEOPMD/ESales YoY
    Sun PharmaSUNPHARMA₹4.49 L Cr40.955.0314.8%21.0%29.0%0.04+11.9%
    Divi's LaboratoriesDIVISLAB₹2.93 L Cr87.1916.8816.2%22.0%43.0%0.00+35.4%
    Torrent PharmaTORNTPHARM₹1.75 L Cr77.889.6726.8%15.0%33.0%0.77+50.8%
    Apollo HospitalsAPOLLOHOSP₹1.27 L Cr56.4011.5522.6%17.0%16.0%0.77+23.0%
    Laurus LabsLAURUSLABS₹1.25 L Cr93.7219.8218.2%18.0%34.0%0.43+33.5%
    Zydus LifesciencesZYDUSLIFE₹1.20 L Cr28.724.3220.1%21.0%24.0%0.50+29.2%
    Dr. Reddy's LabsDRREDDY₹1.17 L Cr41.632.9711.6%13.0%20.0%0.19-1.5%
    Eris LifesciencesERIS₹18,551 Cr26.004.3719.2%14.0%35.0%0.59+12.6%
    Sector median₹24,603 Cr43.685.4615.1%17.0%24.0%0.17+22.7%

    Sector as classified in the tracked universe; medians use every tracked Pharma company, and P/E only profitable ones. Tinted figures beat the median.

    Latest news

    Updated 9h ago

    Headlines about Eris Lifesciences from the last two weeks in the financial press. Stories belong to their publishers; Rajat Finance does not endorse them.

    Key metrics

    P/E (TTM)
    24.8
    Price / Book
    4.47
    ROE (FY26)
    19.2%
    ROCE (latest year)
    14%
    Dividend yield
    0.54%

    Moving averages (NSE)

    20-day
    ₹1,215.94
    Price above
    50-day
    ₹1,230.08
    Price above
    200-day
    ₹1,340.12
    Price below

    Charts & trends

    From company filings. Amounts in ₹ crore.

    Revenue 3Y CAGR
    +22.9%
    Profit 3Y CAGR
    +20.1%
    Revenue YoY (Sep 2026)
    +12.6%
    Profit YoY (Sep 2026)
    +39.6%
    Operating margin
    35.0%
    Net margin
    21.0%

    Revenue, profit & margin - quarterly

    ₹ crore; a loss shows red. Operating margin below, same periods.

    0 Cr250 Cr500 Cr750 Cr1K Cr
    • Revenue
    • Net profit

    Operating margin

    Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Sep 20260%20%40%

    Who owns the company

    % of equity by quarter, latest Sept 2026

    Dec '24Mar '25Jun '25Sept '25Dec '25Mar '26Jun '26Sept '260%25%50%75%100%
    • Promoter
    • DII
    • Public
    • FII

    Cash flows

    Where cash came from and went, by fiscal year (₹ crore)

    Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026-2K Cr-1K Cr0 Cr1K Cr2K Cr
    • Operating
    • Investing
    • Financing
    • Free cash flow

    Return on equity

    Net profit over shareholders' equity, by fiscal year

    FY17FY18FY19FY20FY21FY22FY23FY24FY25FY260%20%40%60%15% screen

    Equity vs debt

    Shareholders' equity against borrowings (₹ crore); the ratio below, same years.

    0 Cr2K Cr4K Cr6K Cr
    • Equity
    • Debt

    Debt to equity

    Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Sep 20260x1x2x

    Dividends per share

    ₹ by fiscal year of the ex-date; the latest year runs to date.

    FY20FY21FY22FY23FY24FY25FY26FY27₹0₹2₹4₹6₹8

    Financial statements

    ₹ Crore
    Quarterly results, oldest period first, figures in rupees crore
    Line itemDec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026Sep 2026
    Sales486551720741727705773792807757873892
    Expenses311402470477477453496504526484577584
    Operating Profit176148250265250252277288282272296308
    OPM %36%27%35%36%34%36%36%36%35%36%34%35%
    Other Income415254843-1722-33
    Interest183360595754495049464746
    Depreciation465476808177716970707273
    Profit before tax11677116129116129161173145159179156
    Tax %12%-4%22%25%25%21%22%22%25%-75%20%-20%
    Net Profit10180909687102125134109279143187
    EPS in Rs₹7.55₹5.22₹6.12₹6.73₹6.15₹6.89₹8.66₹8.82₹7.32₹20.33₹10.28₹13.25

    From company filings, updated 19 Nov 2026. Consolidated figures where the company reports them. Information only, not investment advice.

    Working-capital cycle

    Debtor Days79

    +37 days since Mar 2021

    Inventory Days200

    +55 days since Mar 2021

    Days Payable151

    -6 days since Mar 2021

    Cash Conversion Cycle129

    +99 days since Mar 2021

    Working Capital Days-71

    -135 days since Mar 2021

    Strengths, risks & growth

    ERIS Lifesciences Ltd is engaged in the business of manufacture and marketing of pharmaceutical products. [1]

    Strengths

    None flagged by the checklist.

    Risks

    • Stock is trading at 4.48 times its book value
    • Tax rate seems low
    • Company might be capitalizing the interest cost

    Compounded Sales Growth

    10 Years
    +18%
    5 Years
    +21%
    3 Years
    +23%
    TTM
    +11%

    Compounded Profit Growth

    10 Years
    +17%
    5 Years
    +12%
    3 Years
    +19%
    TTM
    +80%

    Stock Price CAGR

    10 Years
    —
    5 Years
    +12%
    3 Years
    +13%
    1 Year
    -17%

    Return on Equity

    10 Years
    +21%
    5 Years
    +18%
    3 Years
    +16%
    Last Year
    +19%

    Strengths and risks are a machine-generated checklist, not advice; growth is compounded annually over each period.

    Shareholding pattern

    Percentage of shares held by each category at each quarter end
    HolderDec 2025Mar 2026Jun 2026Sept 2026Change
    Promoter54.85%53.92%54.14%54.74%+0.60 pp
    FII6.85%6.39%5.76%5.74%-0.02 pp
    DII20.31%20.35%20.71%20.19%-0.52 pp
    Public17.97%19.33%19.39%19.32%-0.07 pp

    Filed with NSE for Sept 2026: promoters 54.74%, public 45.26%

    Analysts & fund holdings

    90%
    90% recommend buy
    10 analysts cover the stock
    Valuation vs Pharmaceuticals
    P/E26.0 vs 45.2
    Sector P/B6.05
    Beta0.80

    Who holds the shares, quarter by quarter

    Mutual funds 17.98% (-0.90 pp)
    Jun 25
    Sept 25
    Dec 25
    Mar 26
    Jun 26
    Sept 26
    • Promoters54.7%
    • Foreign institutions5.7%
    • Mutual funds18.0%
    • Insurance1.5%
    • Other domestic institutions0.7%
    • Retail2.5%
    • Others16.8%
    Mutual funds holding the most
    Fund% of company% of fund3-month change
    HDFC Small Cap Fund4.05%1.92%-0.18 pp
    Franklin India Small Cap Fund1.50%2.08%-0.01 pp
    HDFC Aggressive Hybrid Fund1.44%1.27%-0.21 pp
    Franklin India Flexi Cap Fund0.95%0.96%-0.01 pp
    DSP Small Cap Fund0.77%0.70%-0.12 pp

    Scorecard

    Performance
    Low
    Valuation
    High
    Growth
    Avg
    Profitability
    High
    Entry point
    Avg
    Red flags
    Low

    Analyst coverage, holdings and scorecard from market data; not a recommendation by Rajat Finance.

    Risk & trend

    From 292 daily sessions to 18 Nov 2026.

    Computed

    Risk

    Volatility (1Y)
    29.8%
    Downside volatility
    27.5%
    Worst 5% of days
    3.1%
    Average of that tail
    4.0%
    Max drawdown (1Y)
    35.6%
    Below its peak
    21.4%

    Against the market

    Beta vs Nifty 50
    0.58
    Correlation
    0.26
    Relative strength (3M)
    -4.7%
    ATR (14)
    3.3%

    Return

    Return 1M
    +16.8%
    Return 3M
    -0.9%
    Return 6M
    -0.3%
    Return 1Y
    -16.0%
    vs 200-day average
    -0.2%

    Momentum

    RSI (14)
    69.6
    MACD histogram
    20.64
    Stochastic %K
    81.1
    ADX (14)
    36.9
    +DI / −DI
    29.9 / 8.1
    Money flow index
    96.2

    Participation

    Delivery (20d avg)
    52.1%
    vs its 60-day baseline
    -1.9 pts
    Volume vs 20-day
    +0.4σ
    Close vs day's VWAP
    -1.5%
    52-week position
    40 / 100

    These describe what this stock's price has already done. They are not forecasts, signals or recommendations, and a dash means the figure was withheld for want of enough history rather than being zero.

    Financial quality

    From consolidated statements to 30 Sept 2026.

    Computed

    Piotroski F-Score

    4 of 6 tested

    • Return on assets positive — passed
    • Operating cash flow positive — not testableno cash flow statement for this period
    • Return on assets improving — passed
    • Cash flow exceeds profit — not testableneeds cash flow and profit against assets
    • Debt to assets falling — passed
    • Current ratio improving — failed
    • No new equity issued — not testableno share count is collected, and financing cash flow mixes equity with debt
    • Operating margin improving — failed
    • Asset turnover improving — passed
    Free cash flow
    ₹241 Cr
    FCF yield
    1.3%
    Cash conversion
    0.83
    Accruals ratio
    0.015
    Net debt
    ₹2,191 Cr
    Net debt / equity
    0.53
    EV / sales
    6.23
    PEG
    0.66
    Capex intensity
    9.5%
    Revenue CAGR
    17.0%
    Profit CAGR
    49.5%

    Computed from filed statements, not filed themselves. A dash means an input was absent, and the score counts only the criteria that could actually be tested.

    Corporate actions

    • dividend
      ₹7.21

      Interim Dividend - Rs 7.21 Per Share

      29 May 2026
      ex-date
    • dividend
      ₹7.35

      Interim Dividend - Rs 7.35 Per Share

      13 Feb 2025
      ex-date
    • other
      Not available — not reported in this filing

      Annual General Meeting

      17 Sept 2024
      ex-date
    • other
      Not available — not reported in this filing

      Annual General Meeting

      15 Sept 2023
      ex-date
    • other
      Not available — not reported in this filing

      Annual General Meeting

      23 Aug 2022
      ex-date
    • dividend
      ₹7.35

      Interim Dividend- Rs 7.35 Per Share

      11 Aug 2022
      ex-date
    • other
      Not available — not reported in this filing

      Annual General Meeting

      23 Aug 2021
      ex-date
    • dividend
      ₹6.01

      Interim Dividend - Rs 6.01 Per Share

      5 Aug 2021
      ex-date
    • other
      Not available — not reported in this filing

      Annual General Meeting

      18 Sept 2020
      ex-date
    • dividend
      ₹5.50

      Interim Dividend - Rs 5.50 Per Share

      13 Aug 2020
      ex-date
    • dividend
      ₹2.87

      Interim Dividend - Rs 2.87 Per Share

      19 Mar 2020
      ex-date
    • other
      Not available — not reported in this filing

      Annual General Meeting

      18 Sept 2019
      ex-date
    • buyback
      Not available — not reported in this filing

      Buyback

      12 Jul 2019
      ex-date
    • other
      Not available — not reported in this filing

      Annual General Meeting

      19 Sept 2018
      ex-date
    • other
      Not available — not reported in this filing

      Annual General Meeting

      20 Sept 2017
      ex-date

    Company announcements

    Company Update
    Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation

    as attached

    Company Update
    Announcement under Regulation 30 (LODR)-Newspaper Publication

    as attached

    AGM/EGM
    Shareholder Meeting / Postal Ballot-Notice of Postal Ballot

    as attached

    Company Update
    Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation

    The Company will host "Eris Investor Meet - 2026" on November 19, 2026

    Company Update
    Announcement under Regulation 30 (LODR)-Earnings Call Transcript

    as attached

    Company Update
    Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome

    as attached

    Company Update
    Announcement under Regulation 30 (LODR)-Investor Presentation

    as attached

    Result
    Financial Results For Quarter And Half Year Ended September 30, 2026

    as attached

    Board Meeting
    Board Meeting Outcome for Outcome Of Board Meeting

    as attached

    Company Update
    Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation

    As Attached

    Company Update
    Board Meeting Intimation For Consideration And Approval Of The Financial Results For The Period Ended September 30, 2026

    As Attached

    Board MeetingPrice-sensitive
    Board Meeting Intimation for Consideration And Approval Of The Financial Results For The Period Ended June 30, 2026

    Eris Lifesciences Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 26/10/2026 ,inter alia, to consider and approve Financial Results

    Company Update
    Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018

    As Attached

    Company Update
    Announcement under Regulation 30 (LODR)-Resignation of Director

    As Attached

    Insider Trading / SAST
    Closure of Trading Window

    As Attached

    Filed with BSE (scrip 540596); the last 45 days. Documents open at bseindia.com.

    SEBI filings & orders

    From SEBI's website. An order may concern the company, its officers or trading in its shares, and may be under appeal - read the order itself. Personal identifiers are withheld.

    Buybacks, open offers & rights issues

    • Buyback - POST BUYBACK PUBLIC ADVERTISEMENT

      ERIS LIFESCIENCES LIMITED - POST BUYBACK PUBLIC ADVERTISEMENT

      27 Jan 2020
      Read on SEBI
    • Buyback

      Eris Lifesciences Limited

      26 Dec 2019
      Read on SEBI
    • Buyback - Draft Letter of Offer

      Eris Lifesciences Ltd. - Draft Letter of Offer

      16 Jul 2019
      Read on SEBI
    • Buyback - Public Announcement

      Eris Lifesciences Ltd. - Public Announcement

      9 Jul 2019
      Read on SEBI

    Documents

    Credit ratings

    Documents open at BSE or the rating agency that issued them.

    Sourced from the company's NSE XBRL filing dated 26 Oct 2026 (unaudited). View the source filing. Figures are as filed and are not investment advice.

    FAQ

    Eris Lifesciences: common questions

    Answered from the figures on this page.

    Eris Lifesciences last traded at ₹1,337.10 (NSE, as of 18 Nov 2026). The last session moved it down 1.78%.

    Eris Lifesciences is valued at about ₹18,551 crore (NSE, as of 18 Nov 2026).

    Eris Lifesciences trades at a price-to-earnings ratio of 26.00 (NSE, as of 18 Nov 2026). The P/E compares the share price with earnings per share, so it is only comparable between companies in the same industry.

    Eris Lifesciences has traded between ₹1,069.00 and ₹1,740.00 over the past 52 weeks, to 18 Nov 2026. It is currently 40% of the way up that range.

    Eris Lifesciences (ERIS) is classified under Pharma on this site's screener.